Definitive Contract HHSO100201500008C
Award Date
9/14/15
Potential Completion Date
8/16/24
Potential Value
$93M
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Netherlands
Solicitation Procedures
Basic Research
Number Of Offers Received
1
Legislative Mandate
Clinger Cohen Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
<p>This is a cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Janssen Vaccines & Prevention B.V. (JPC), a foreign-owned for-profit organization. The $196,408,488.00 contract does not have a set-aside designation and has an ultimate completion date of March 30, 2026. The contract was awarded on September 28, 2017.</p>
This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract, with a ceiling value of $86,670,401.90, is for biomedical (advanced) products and services. The prime contractor is Janssen Vaccines & Prevention B.V., a foreign-owned for-profit organization. The contract does not have a set-aside designation and has an ultimate completion date...
This is a $228,598,975.00 definitive cost-sharing contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Janssen Research & Development, LLC. The contract was issued under ASPR's Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) focused on the advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Janssen Vaccines & Prevention B.V. (doing business as JPC), a foreign-owned for-profit organization. The contract is for the "Application of Platform Technologies for the Development of Therapeutics for Biodefense" and has a ceiling value of $100,958,063.00. The contract type is Cost Plus Fixed Fee, with an ultimate completion date of August 14, 2014. The...
This is a Cost Plus Fixed Fee contract awarded by the Department of Health and Human Services' National Institutes of Health (DHHS NIH) to Janssen Vaccines & Prevention B.V., a foreign-owned, for-profit organization, for the production of adenoviral vector vaccines. The contract has a potential value of $82,806,174.12 and a completion date of September 14, 2011. The contract is not set aside for any specific business type. The award is not associated with a larger vehicle. The contract is...
This is a $1,628,690,592.00 definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Bavarian Nordic A/S, a for-profit biotechnology company based in Denmark. The contract has a firm fixed price pricing type and an ultimate completion date of September 26, 2027. It is not a set-aside contract. Bavarian Nordic A/S is providing the government with various goods and services, including endpoint titer analysis services involving...
This is a $1,403,362,669.10 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company manufacturing medical countermeasures and pharmaceuticals. The contract, which has a period of performance through September 29, 2026, is for the development of filovirus treatments. Emergent has received over $1.3...
This is a federal contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency within the U.S. Department of Health and Human Services, to Profectus Biosciences, Inc., a small business contractor. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, with a ceiling value of $7,524,330.27 and a period of performance through November 30, 2016. The contract is for the GMP (Good Manufacturing Practice) manufacture of the...
This is a Cost Plus Fixed Fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Sanofi Pasteur Biologics, LLC for the production and testing of a Modified Vaccinia Ankara (MVA) vaccine. The contract award has a ceiling value of $74,940,566.62 and an ultimate completion date of February 6, 2015. The contract is not designated as a set-aside. As a child company of the Sanofi group, Sanofi...
This is a cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Vaxine PTY LTD, a for-profit organization located in Australia. The $18,541,473.00 contract is for the "ADVANCED DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES". The contract has an end date of August 14, 2023 and was initially awarded on September 20, 2018. This contract...